logo-loader

Viralytics hits enrolment target for Phase 2 trial of anti-cancer drug

Last updated: 13:40 08 Jan 2014 AEDT, First published: 12:40 08 Jan 2014 AEDT

au_medical_350_52cc932de4a45

Viralytics (ASX: VLA, OTCQX:VRACY) has achieved the target enrolment for the Phase 2 melanoma trial for its CAVATAK anti-cancer drug for the treatment of late stage melanoma.

The 54th patient has been injected with the drug while interim results show that 14 of the 40 evaluable patients reaching the six month immune related Progression Free Survival target.

In addition, there is promising one year survival data with 12 of first 20 patients still alive at that stage.

The Phase 2 trial is a single arm study being conducted at 11 US cancer clinics to investigate the safety and efficacy of intratumoral CAVATAK in patients with late stage malignant melanoma.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 30 minutes ago